指南与共识冠心病

丹麦全国高危与极高危患者LDL-C达标现状及指南实施模拟评估

Nationwide LDL-C goal attainment in high-risk and very-high-risk patients in Denmark: real-world lipid management and simulated impact of guideline implementation
RSS 订阅 · Open Heart

研究评估真实世界LDL-C达标率,并模拟逐步强化降脂治疗(他汀、依折麦布、PCSK9抑制剂)在丹麦与欧洲指南下的临床和经济影响。结果显示早期更广泛采用联合降脂治疗可显著提高达标率、减少心血管事件并节省医疗费用。

要点

  • 丹麦指南下高危一级预防真实世界LDL-C达标率为39.8%,欧洲指南下仅15.1%。
  • 二级预防在两种指南下真实世界达标率均为18.8%。
  • 模拟优化实施后丹麦指南一级预防达标率升至91.9%,欧洲指南二级预防达标率升至96.8%。

核心结论

  • 早期和更广泛采用联合降脂治疗可大幅提高LDL-C达标率,减少心血管事件并产生可观的医疗费用节省。

研究设计与样本

  • 模拟模型评估逐步强化降脂治疗(他汀、依折麦布、PCSK9抑制剂)对LDL-C达标、可预防心血管事件和临床事件费用节省的影响。

主要发现

  • 一级预防真实世界LDL-C达标率:丹麦指南下39.8%,欧洲指南下15.1%。
  • 二级预防真实世界LDL-C达标率在两种指南下均为18.8%。
  • 优化实施后丹麦指南一级预防达标率91.9%、二级预防63.5%;欧洲指南一级预防75.8%、二级预防96.8%。
  • 丹麦指南实施每年可预防589例卒中、491例心肌梗死、581例血运重建和196例心血管死亡。

关键数值与推荐

  • 丹麦指南与欧洲指南在LDL-C目标阈值、治疗推荐和高级降脂治疗可及性方面存在差异。
  • 模拟强化方案包括他汀、依折麦布和PCSK9抑制剂,并在丹麦现行报销限制背景下评估。

临床怎么用

  • 在高危和极高危ASCVD患者中应早期启动联合降脂治疗,而非延迟强化。
  • 采用更严格的欧洲指南LDL-C目标可进一步减少事件但需更高强度治疗和药物可及性支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aim Low-density lipoprotein cholesterol (LDL-C) goal attainment remains suboptimal among individuals with or at risk for atherosclerotic cardiovascular disease (ASCVD). We evaluated contemporary nationwide real-world LDL-C goal attainment in Denmark and the clinical and economic impact of simulated implementation of the 2020 Danish and 2019 European guidelines, which differ in LDL-C goal thresholds, treatment recommendations and access to advanced lipid-lowering therapy. Methods In this nationwide registry-based cohort study, we included all Danish residents aged 30–85 years classified as high-risk or very-high-risk for ASCVD, with LDL-C measurements between January 2022 and December 2023 and repeat measurements 6–15 months later. A simulation model estimated the impact of stepwise intensification of lipid-lowering therapy, including statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, on LDL-C goal attainment, preventable cardiovascular events and clinical event cost savings within the context of current Danish reimbursement restrictions. Results Among 487 962 individuals (336 705 primary prevention and 151 257 secondary prevention), LDL-C goal attainment at follow-up in primary prevention was 39.8% under the Danish guideline and 15.1% under the European guideline and 18.8% in secondary prevention under both guidelines. With optimal implementation, attainment increased to 91.9% (primary) and 63.5% (secondary) under the Danish guideline, and to 75.8% (primary) and 96.8% (secondary) under the European guideline. Compared with real-world outcomes, implementation of the Danish guideline could annually prevent 589 strokes, 491 myocardial infarctions, 581 revascularisations and 196 cardiovascular deaths. Implementation of the European guideline would avert an additional 179 strokes, 156 myocardial infarctions, 166 revascularisations and 67 cardiovascular deaths, corresponding to annual clinical event cost savings of 15.8 million. Conclusions Early and broader adoption of combination lipid-lowering therapy could substantially improve LDL-C goal attainment, reduce cardiovascular events and generate meaningful healthcare cost savings.

来源:Open Heart,查看原文。版权归原作者所有。

引用

  1. Open Heart:Nationwide LDL-C goal attainment in high-risk and very-high-risk patients in Denmark: real-world lipid management and simulated impact of guideline implementation

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。